knowledge -WSS

knowledge

author：explore 2025-09-06 04:33:50 - browse：3197

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Why health records don't always know when patients are dead

knowledge

WSS

Editas, Vertex strike deal on CRISPR

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Hospitals owned by private equity see complications spike 25%

SEC charges former device maker CEO with $41 million fraud

Prosecutors seek bail revocation for FTX founder Sam Bankman

Virtual care provider acquires bankrupt Pear's prescription apps

focus

knowledge

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

Hollywood unions extend contract negotiations for actors

HCA sued by state AG for quality issues at Mission Health

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CRISPR gene editing developments we’re watching in 2024

Jerome Adams on the need for new antivirals for Covid

What STAT readers think about the FDA and patient advocacy

Dobbs anniversary: the lost opportunity of abortion as health care

Virtual care provider acquires bankrupt Pear's prescription apps

Wikipedia

Virtual care provider acquires bankrupt Pear's prescription apps

Editas, Vertex strike deal on CRISPR

Calls for Trump's election interference trial to be televised part of long debate

Virtual care provider acquires bankrupt Pear's prescription apps

SNAP should offer more nutrition education

Lifetime voting ban for felony convictions struck down in Mississippi

hotspot

knowledge

hotspot

focus